William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today.
Sami Corwin has given his Buy rating due to a combination of factors including the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding Krystal Biotech’s Vyjuvek. This recommendation sets the stage for European approval and subsequent commercial launch in mid-2025, starting in Germany and followed by France. The support for at-home administration is seen as a favorable aspect, aligning with the U.S. market where a significant majority of patients opt for home treatments.
Additionally, the analyst views this development as a significant milestone that could drive Vyjuvek’s commercial success further. The anticipated European label is expected to mirror the U.S. label, which could enhance market penetration. The financial projections for Vyjuvek are strong, with expected worldwide sales exceeding $1.0 billion by 2030, driven largely by the U.S. market. These factors collectively contribute to the Buy rating, reflecting confidence in Krystal Biotech’s growth potential and market strategy.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $221.00 price target.